HIV Vaccines: Current and Future Directions
HIV/AIDS is a leading cause of mortality and morbidity worldwide and an HIV vaccine would be the ultimate prevention and control strategy.
The reader will have a better understanding of the HIV vaccine development field.
Promising results from an early safety trial (based on the previous RV144 Vaccine Trial) with a potential HIV vaccine has paved the way for a major new study.
An 18-month trial with a candidate vaccine dubbed HVTN100 drew on 252 participants at six sites in South Africa, one of the countries hardest-hit by an epidemic that has claimed more than 30-million lives worldwide since the 1980s. The next phase of the trial, dubbed HVTN702, started in November 2016 with the recruitment of 5,400 South African men and women aged between 18 to 25 at high risk of contracting HIV..
The reader will learn more about recent vaccine efficacy trials and advancements as well as the current challenges and future directions in the field of vaccine research.
Instruction for this Module
- Read the supplied reading material and complete the quiz at the end
- You need to pass the quiz and complete the course rating to generate the module certificate at the end
- You have three attempts to pass the quiz
- The pass grade is 70%
- Please click on the CPD certificate link to claim your certificate and to update your CPD Manager
RSA TEL: 086 1000 381 | Int. Tel: 021 975 2602